|Chemical and physical data|
|Molar mass||445.47 g·mol−1|
|3D model (JSmol)|
Basmisanil (INN; developmental codes RG-1662 and RO5186582) is a highly selective inverse agonist/negative allosteric modulator of α5 subunit-containing GABAA receptors which is under development by Roche for the treatment of cognitive impairment associated with Down syndrome. As of June 2016, it is no longer studied.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|